Prostate Cancer - Results from #23480

AUA 2013 - Session Highlights: Development and validation of the biopsy-based genomic prostate score (GPS) as a predictor of high grade or extracapsular prostate cancer to improve patient selection for active surveillance May 13, 2013

Maximizing dosimetric benefits of IMRT in the treatment of localized prostate cancer through multicriteria optimization planning - Abstract May 13, 2013

Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer - Abstract May 13, 2013

Three-dimensional summation of rectal doses in brachytherapy combined with external beam radiotherapy for prostate cancer - Abstract May 13, 2013

AUA 2013 - Video Presentation: Treatment practice patterns in metastatic castration-resistant prostate cancer (mCRPC) patients prior to receiving sipuleucel-T: Data from PROCEED May 13, 2013

Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: Results from a multi-institutional phase 1 study - Abstract May 13, 2013

AUA 2013 - Session Highlights: AUA Guidelines: Radiation after prostatectomy May 13, 2013

AUA 2013 - Podcast: Dr. Deepak A. Kapoor, president of the Large Urology Group Practice Association (LUGPA) gives a response to the newly-released AUA guidelines on early detection of prostate cancer in an exclusive interview with UroToday May 13, 2013

High diagnostic ability of multi-parametric magnetic resonance imaging in detecting anterior prostate cancer missed by transrectal 12-core biopsy - Abstract May 13, 2013

Comparative effectiveness review: Prostate cancer antigen 3 (PCA3) testing for the diagnosis and management of prostate cancer - Abstract May 13, 2013

Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases - Abstract May 13, 2013

Efficacy and toxicity of conventionally fractionated pelvic radiation with a hypofractionated simultaneous versus conventionally fractionated sequential boost for patients with high-risk prostate cancer - Abstract May 13, 2013

The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer - Abstract May 13, 2013

Four new drugs on the market: Abiraterone, belatacept, vandetanib and fidaxomycine - Abstract May 10, 2013

A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy - Abstract May 10, 2013

Targeted MRI-guided prostate biopsies for the detection of prostate cancer: Initial clinical experience with real-time 3-dimensional transrectal ultrasound guidance and magnetic resonance/transrectal ultrasound image fusion - Abstract May 10, 2013

Hypofractionated external-beam radiotherapy for prostate cancer - Abstract May 10, 2013

Dosimetric effects of weight loss or gain during volumetric modulated arc therapy and intensity-modulated radiation therapy for prostate cancer - Abstract May 10, 2013

Toxicity after external beam radiotherapy for prostate cancer: An analysis of late morbidity in men with diabetes mellitus - Abstract May 10, 2013

Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: Observation and implication - Abstract May 9, 2013

Page 1175 of 1448